Colorectal cancer (CRC) leads to approximately 550,000 annual deaths worldwide and is
thus a major public health concern [1]. Once an individual is diagnosed with CRC, the …

Abstract Cyclooxygenase 2 (COX-2), also called prostaglandin endoperoxide synthase 2, is
involved in colorectal tumor development. This review deals with particular questions raised …

Aspirin was commercialized more than a 100 years ago. Today, this compound is still widely
prescribed, and new mechanisms of action and indications are being tested. Inhibition of …

Background Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of
adenomas. Cyclooxygenase-2 (COX-2), one of its main target enzymes, is reportedly over …

Prevention of human diseases has become a major focus of biomedical investigators
around the world. Our current screening and treatment regimens for colorectal cancer are …

Numerous experimental, epidemiologic, and clinical studies suggest that nonsteroidal anti-
inflammatory drugs (NSAIDs), particularly the highly selective cyclooxygenase (COX)-2 …

Colorectal cancer is one of the commonest malignancies worldwide. Recently, there has
been much speculation regarding the role of cyclooxygenase-2 (COX-2) suppression in …

Background—Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal
adenomas but have been associated with increased cardiovascular risk. Methods and …

The cyclooxygenase-2 (COX-2) enzyme has a fundamental role in the carcinogenesis of
colorectal cancer. The anticarcinogenic mechanisms of NSAIDs are not completely …

Epidemiological and animal studies suggest that nonsteroidal anti-inflammatory drugs
(NSAIDs) may reduce colon cancer risk. NSAIDs nonselectively inhibit both the constitutive …